{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:58:08Z","timestamp":1790413088599,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bcp.2019.03.015","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T11:52:55Z","timestamp":1552477975000},"page":"440-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas"],"prefix":"10.1016","volume":"163","author":[{"given":"Ros\u00e2ngela Mayer","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Paulo","family":"Agnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Delgobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Oliveira","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos P.","family":"Thom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-8905","authenticated-orcid":false,"given":"Luana","family":"Heimfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Cl\u00e1udio Fonseca","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfeu","family":"Zanotto-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.03.015_b0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/cns.14.55","article-title":"Treating recurrent glioblastoma: an update","volume":"4","author":"Kamiya-Matsuoka","year":"2015","journal-title":"CNS Oncol. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2014.12.044","article-title":"Autophagy inhibition improves the efficacy of curcumin\/temozolomide combination therapy in glioblastomas","volume":"358","author":"Zanotto-Filho","year":"2015","journal-title":"Cancer Lett. Ireland"},{"key":"10.1016\/j.bcp.2019.03.015_b0020","article-title":"Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage","volume":"8","author":"Knizhnik","year":"2013","journal-title":"PLoS One. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0025","article-title":"Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells","volume":"6","author":"Filippi-Chiela","year":"2011","journal-title":"PLoS One U.S."},{"issue":"3","key":"10.1016\/j.bcp.2019.03.015_b0030","first-page":"198","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Gen. Dis."},{"key":"10.1016\/j.bcp.2019.03.015_b0035","article-title":"Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment","volume":"4","author":"Sui","year":"2013","journal-title":"Cell Death Dis. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0040","doi-asserted-by":"crossref","first-page":"9349","DOI":"10.1158\/0008-5472.CAN-06-1597","article-title":"Autophagy in cancer: good, bad, or both?","volume":"66","author":"Hippert","year":"2006","journal-title":"Cancer Res. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2012.03.002","article-title":"Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells","volume":"320","author":"Guo","year":"2012","journal-title":"Cancer Lett. Ireland"},{"key":"10.1016\/j.bcp.2019.03.015_b0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev-genet-102808-114910","article-title":"Regulation mechanisms and signaling pathways of autophagy","volume":"43","author":"He","year":"2009","journal-title":"Annu Rev Genet. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0055","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.4161\/auto.25664","article-title":"Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells","volume":"9","author":"Chiao","year":"2013","journal-title":"Autophagy. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0060","article-title":"The Inhibition of microRNA-128 on IGF-1-activating mTOR signaling involves in Temozolomide-induced glioma cell apoptotic death","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0065","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/15384047.2015.1046022","article-title":"The interplay between DNA repair and autophagy in cancer therapy","volume":"16","author":"Zhang","year":"2015","journal-title":"Cancer Biol. Ther. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0070","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/15548627.2015.1009795","article-title":"Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage","volume":"11","author":"Filippi-Chiela","year":"2015","journal-title":"Autophagy. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0075","first-page":"75","article-title":"Management of cutaneous T cell lymphoma: new and emerging targets and treatment options","volume":"4","author":"Li","year":"2012","journal-title":"Cancer Manag Res. New Zealand"},{"key":"10.1016\/j.bcp.2019.03.015_b0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat Biotechnol. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0085","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1073\/pnas.1204429109","article-title":"Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death","volume":"109","author":"Gammoh","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0090","article-title":"Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe","volume":"5","author":"Cornago","year":"2014","journal-title":"Cell Death Dis. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0095","article-title":"Vorinostat(SAHA) promotes hyper-radiosensitivity in wild type p53 human glioblastoma cells","author":"Diss","year":"20142","journal-title":"J. Clin. Oncol. Res. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0100","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1158\/1078-0432.CCR-12-0560","article-title":"Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts","volume":"18","author":"Kitange","year":"2012","journal-title":"Clin. Cancer Res. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jnutbio.2011.02.015","article-title":"The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma","volume":"23","author":"Zanotto-Filho","year":"2012","journal-title":"J. Nutr. Biochem. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0110","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1158\/1078-0432.CCR-06-0593","article-title":"The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas","volume":"12","author":"Newcomb","year":"2006","journal-title":"Clin. Cancer Res. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12885-015-1538-9","article-title":"A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model","volume":"15","author":"Towner","year":"2015","journal-title":"BMC Cancer. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0120","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1349-7006.2006.00208.x","article-title":"Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy","volume":"97","author":"Szatmari","year":"2006","journal-title":"Cancer Sci. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.canlet.2015.02.012","article-title":"The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells","volume":"360","author":"Lee","year":"2015","journal-title":"Cancer Lett. Ireland"},{"key":"10.1016\/j.bcp.2019.03.015_b0130","first-page":"2787","article-title":"Autophagy inhibition potentiates SAHAmediated apoptosis in glioblastoma cells by accumulation of damaged mitochondria","volume":"39","author":"Lohitesh","year":"2018","journal-title":"Oncol Rep. Greece"},{"key":"10.1016\/j.bcp.2019.03.015_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-014-1686-9","article-title":"Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells","volume":"122","author":"Hori","year":"2015","journal-title":"J Neurooncol. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0140","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.18632\/oncotarget.13680","article-title":"SAHA and\/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0145","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin. Cancer Res. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0150","unstructured":"Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. 2013. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. 1\u201312."},{"key":"10.1016\/j.bcp.2019.03.015_b0155","doi-asserted-by":"crossref","unstructured":"Hippert MM, Toole PSO, Thorburn A, Hippert MM, Toole PSO, Thorburn A. 2014. Autophagy in Cancer: Good, Bad, or Both? Autophagy in Cancer: Good, Bad, or Both? 9349\u20139351.","DOI":"10.1158\/0008-5472.CAN-06-1597"},{"issue":"2","key":"10.1016\/j.bcp.2019.03.015_b0160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.freeradbiomed.2011.10.487","article-title":"Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy","volume":"52","author":"Lin","year":"2012","journal-title":"Free Rad. Biol. Med."},{"key":"10.1016\/j.bcp.2019.03.015_b0165","doi-asserted-by":"crossref","unstructured":"Chiao M, Cheng W, Yang Y, Shen C, Chiao M, Cheng W, et al. 2013 glioblastoma stem cells Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells 8627.","DOI":"10.4161\/auto.25664"},{"key":"10.1016\/j.bcp.2019.03.015_b0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrm3735","article-title":"Self-consumption: the interplay of autophagy and apoptosis","volume":"15","author":"Marino","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-016-0303-5","article-title":"Targeting autophagy to sensitive glioma to temozolomide treatment","volume":"35","author":"Yan","year":"2016","journal-title":"J. Exp. Clin. Cancer Res. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0180","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/2014.9.FOCUS14504","article-title":"Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy","volume":"37","author":"Golden","year":"2014","journal-title":"Neurosurg Focus. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12929-016-0296-6","article-title":"Suberoylanilide hydroxamic acid represses glioma stem-like cells","volume":"23","author":"Hsu","year":"2016","journal-title":"J. Biomed. Sci. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"10","author":"Rasmussen","year":"2016","journal-title":"Mol. Oncol. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0195","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1158\/1078-0432.CCR-06-1802","article-title":"A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer","volume":"12","author":"Rubin","year":"2006","journal-title":"Clin. Cancer Res. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0200","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1349-7006.2009.01237.x","article-title":"Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors","volume":"100","author":"Fujiwara","year":"2009","journal-title":"Cancer Sci. England"},{"key":"10.1016\/j.bcp.2019.03.015_b0205","article-title":"Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine","volume":"14","author":"Briceno","year":"2003","journal-title":"Neurosurg Focus. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0210","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-144-5-200603070-00008","article-title":"Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial","volume":"144","author":"Sotelo","year":"2006","journal-title":"Ann. Intern. Med. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0215","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.surneu.2006.08.080","article-title":"Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme","volume":"67","author":"Briceno","year":"2007","journal-title":"Surg. Neurol. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0220","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","article-title":"Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience","volume":"31","author":"Bezecny","year":"2014","journal-title":"Med Oncol. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1634\/theoncologist.2017-0501","article-title":"Phase II study of bevacizumab and vorinostat for patients with recurrent world health organization grade 4 malignant glioma","volume":"23","author":"Ghiaseddin","year":"2018","journal-title":"Oncologist. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-017-2724-1","article-title":"Phase I\/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas","volume":"137","author":"Peters","year":"2018","journal-title":"J. Neurooncol. U.S."},{"key":"10.1016\/j.bcp.2019.03.015_b0235","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-09-1039","article-title":"Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks","volume":"15","author":"Palmieri","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:09:39Z","timestamp":1757768979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219301017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":47,"alternative-id":["S0006295219301017"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.03.015","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}